Patent holders — those scrappy inventors and cash-strapped startups — just caught a massive break. The USPTO’s IPR institution rate has cratered 43%, from 65% in late 2024 to a measly 37% by early 2026. That’s not some abstract stat; it’s fewer nights sweating over challenger petitions that could gut your IP overnight.
And here’s the kicker: appeals pendency slashed from 28 months to just over 9. Real people — think biotech founders or software devs — get decisions faster, cash flow intact, without the two-year limbo.
The raw numbers.
October 2024: 65% institution rate. February 2026: 37%. Denials outpacing grants since April 2025, every month but one. Inventory? Down 90% from 2012’s 26,570 peak to 1,866 today.
Acting Vice Chief Judge Stacey White nailed it during the USPTO Hour webinar:
“From an average [appeals] pendency of over two years/ 28 months as of May 2025, pendency has reached just over 9 months as of April 1, 2026.”
Sustained effort, she said. Disciplined management. But let’s call it what it is: deliberate throttle on IPR floodgates.
Why Has the IPR Institution Rate Plummeted?
Blame — or credit — Director discretion. Back in March 2025, Acting Director Coke Morgan Stewart’s memo invoked 35 U.S.C. 314(a) and 324(a). PTAB had to prioritize ex parte appeals, statutory must-dos. IPRs and PGRs? Suddenly optional.
John Squires ramped it up, taking all IPR calls himself by October 2025. Result: 600 discretionary denials since. Numbers flipped — grants used to dwarf denials; now it’s denial city.
This isn’t random. PTAB Chief APJ Kalyan Deshpande confirmed the shift. Market dynamic? Challengers — often Big Tech or NPEs — filed IPRs like candy pre-2025. Now? They’re hitting walls.
Look, patent owners always argued IPRs skewed against them. Stats bore that out: 80%+ invalidation rates early on. USPTO’s move rebalances, but skeptics whisper politics. Foreign actors, anyone?
RPI Crackdown Hits Foreign Challengers Hard
Enter real party in interest (RPI) wars. Squires’ memo to APJs: petitioners, name everyone upfront or bust. Echoed in January 2026’s Yangtze Memory v. Micron — vacated two institutions because Yangtze (Chinese firm) hid RPIs.
Micron disputed; Yangtze flopped on rebuttal. Squires: prior lax standards let state-backed players game PTAB. Unintended? Sure. Fix? Ironclad RPI checks pre-institution.
Acting Deputy Chief APJ Michelle Ankenbrand urged early flags:
“If you think there’s an RPI issue once you review a petition that’s the time when you should raise the RPI issue with the Office.”
Post-response? Trickier — conflicts, panels assigned. Smart money surfaces issues day one.
My take: this shields U.S. innovation from offshore IP raids. Unique angle — remember the 2010s PTAB explosion? Biotech stocks tanked 20-30% on IPR fears (per PitchBook data). Investors fled. Today’s pivot? Could lure them back, stabilizing valuations. Bold prediction: expect 20% uptick in patent-heavy IPOs by 2028 if this holds.
But hype alert. USPTO touts efficiency; critics cry overreach. Squires’ March 2026 memo adds U.S. manufacturing factors for discretion. Patent owners eyeing that? File early — post-institution requests? Denied, per Ankenbrand.
Faster Appeals: The Hidden Gem
Pendency plunge steals the show. 28 months to 9. Inventory gutted 90%. White credits discipline, but it’s workload triage. Ex parte appeals first — IPRs wait in line.
For real people: inventors appeal rejections quicker. No more two-year black hole draining VC bucks. Tech firms? Allocate legal budgets elsewhere — R&D, not appeals limbo.
Market ripple: stronger patents mean bolder licensing. Challengers pivot to district court — costlier, slower. Win for holders.
Skepticism check. Is this sustainable? 1,866 appeals sounds lean, but filings tick up? Pressure builds. Deshpande says 600 discretions done; more coming.
And that U.S. manufacturing angle — Squires’ latest. No briefs yet, timing too fresh. But watch: favors domestic players, irks importers. Geopolitics in patent stats.
What Does a 43% IPR Drop Mean for Patent Strategy?
Challengers: rethink. Discretionary denial briefs now table stakes. RPIs? Bulletproof ‘em. Owners: use Fintiv, 325(d), now manufacturing hooks.
Historical parallel — SAS Institute v. Iancu (2018) mandated full trials post-institution. Killed half the workload. This? Pre-institution cull, smarter.
Position: USPTO’s strategy makes sense. Backlog crushed, fairness restored. No more PTAB as cheap invalidation mill. But — em-dash — if abuse creeps (over-denial), Congress stirs.
Investors, note: IP-intensive sectors (pharma, semis) rally on this. NPEs scramble.
🧬 Related Insights
- Read more: Buddhism Sounds AI Alarm: Recursive Loops Threaten Freedom of Attention
- Read more: EU AI Act: 14 Countries Haven’t Even Picked Their Watchdogs Yet
Frequently Asked Questions
Will IPR denials make patents bulletproof?
No — just harder to challenge. District courts still game. Institutions down, but merits matter more.
How does PTAB pendency drop affect startups?
Huge. 9 months vs. 28 means faster market entry, preserved runway. VCs love it.
What’s next for USPTO Director discretion?
More factors like U.S. manufacturing. File discretionary briefs early — post-institution? Forget it.
